Neovasc’ COO Bill Little talked to Medtech Insight about the company’s plans to develop its Reducer transcatheter device to treat cardiac angina associated with or without obstructive coronary disease.

Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.

FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.

Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.